SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
08 2021
Historique:
received: 22 12 2020
revised: 29 03 2021
accepted: 29 04 2021
pubmed: 2 6 2021
medline: 4 8 2021
entrez: 1 6 2021
Statut: ppublish

Résumé

Quantitative viral load assays have transformed our understanding of viral diseases. They hold similar potential to advance COVID-19 control and prevention, but SARS-CoV-2 viral load tests are not yet widely available. SARS-CoV-2 molecular diagnostic tests, which typically employ real-time RT-PCR, yield semiquantitative results only. Droplet digital RT-PCR (RT-ddPCR) offers an attractive platform for SARS-CoV-2 RNA quantification. Eight primer/probe sets originally developed for real-time RT-PCR-based SARS-CoV-2 diagnostic tests were evaluated for use in RT-ddPCR; three were identified as the most efficient, precise, and sensitive for RT-ddPCR-based SARS-CoV-2 RNA quantification. For example, the analytical efficiency for the E-Sarbeco primer/probe set was approximately 83%, whereas assay precision, measured as the coefficient of variation, was approximately 2% at 1000 input copies/reaction. Lower limits of quantification and detection for this primer/probe set were 18.6 and 4.4 input SARS-CoV-2 RNA copies/reaction, respectively. SARS-CoV-2 RNA viral loads in a convenience panel of 48 COVID-19-positive diagnostic specimens spanned a 6.2log

Identifiants

pubmed: 34062285
pii: S1525-1578(21)00136-7
doi: 10.1016/j.jmoldx.2021.04.014
pmc: PMC8164350
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

907-919

Informations de copyright

Copyright © 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Natalie N Kinloch (NN)

Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia.

Gordon Ritchie (G)

Division of Medical Microbiology and Virology, St Paul's Hospital, Vancouver, British Columbia; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Winnie Dong (W)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia.

Kyle D Cobarrubias (KD)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia.

Hanwei Sudderuddin (H)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia.

Tanya Lawson (T)

Division of Medical Microbiology and Virology, St Paul's Hospital, Vancouver, British Columbia.

Nancy Matic (N)

Division of Medical Microbiology and Virology, St Paul's Hospital, Vancouver, British Columbia; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Julio S G Montaner (JSG)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Victor Leung (V)

Division of Medical Microbiology and Virology, St Paul's Hospital, Vancouver, British Columbia; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Marc G Romney (MG)

Division of Medical Microbiology and Virology, St Paul's Hospital, Vancouver, British Columbia; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Christopher F Lowe (CF)

Division of Medical Microbiology and Virology, St Paul's Hospital, Vancouver, British Columbia; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Chanson J Brumme (CJ)

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: cbrumme@bccfe.ca.

Zabrina L Brumme (ZL)

Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia. Electronic address: zbrumme@sfu.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH